The combination of DFP-14323 and low-dose afatinib was considered to have the potential for future clinical utility for EGFR mutation-positive NSCLC and is evaluating this combination therapy in uncommon EGFR mutation-positive NSCLC in Japan.
Hiroshige Yoshioka, Masahide Mori, N. Katakami et al.· Therapeutic Advances in Medi...· 0 citations
Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. Here we report long-term clinical outcomes with first-...
Makoto Nishio, H. Hayashi, Yasushi Goto et al.· International Journal of Cli...· 0 citations
Background Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. Erlotinib plus an angiogenesis inhibitor (erlotinib+A) has demonstrated efficacy in controlling malignant pleural effusion (MPE) through reduction of vascular...
T. Hata, T. Yamada, Koji Mikami et al.· Translational Lung Cancer Re...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.